Contents

x Editors’ Message
xi Reviewers
xii Continuing Medical Education Information

Ham-Wasserman Lecture

1 Therapeutic development and current uses of BCL-2 inhibition
ANDREW W. ROBERTS

A Map for the Changing Landscape of CLL

10 Approaches for relapsed CLL after chemotherapy-free frontline regimens
LINDSEY E. ROEKER AND ANTHONY R. MATO

18 EVIDENCE-BASED MINIREVIEW
Treatment of relapsed chronic lymphocytic leukemia after venetoclax
MEGHAN C. THOMPSON AND ANTHONY R. MATO

24 Chemotherapy-free frontline therapy for CLL: is it worth it?
JOANNA M. RHODES AND JACQUELINE C. BARRIENTOS

33 Standard treatment approaches for relapsed/refractory chronic lymphocytic leukemia after frontline chemoimmunotherapy
CAROL MORENO

Acute Myeloid Leukemia—So Many Treatment Options; How Do You Decide?

41 Does patient fitness play a role in determining first-line treatment of acute myeloid leukemia?
EVAN C. CHEN AND JACQUELINE S. GARCIA

51 How to approach shared decision making when determining consolidation, maintenance therapy, and transplantation in acute myeloid leukemia
ALISON R. WALKER

57 Management of toxicities associated with targeted therapies for acute myeloid leukemia: when to push through and when to stop
EUNICE S. WANG AND JEFFREY BARON

Advances in the Laboratory Assessment of Hemostatic and Thrombotic Disorders

67 “TEG talk”: expanding clinical roles for thromboelastography and rotational thromboelastometry
RITA SELBY

76 Improving interpretation of genetic testing for hereditary hemorrhagic, thrombotic, and platelet disorders
MICHELE P. LAMBERT

82 EVIDENCE-BASED MINIREVIEW
Laboratory surveillance of immune-mediated thrombotic thrombocytopenic purpura
ANG LI AND JOHANNA A. KREMER HOVINGA
Aggressive Lymphomas: What Novel Approaches Are Ready for Prime Time?

85 Can we use epigenetics to prime chemoresistant lymphomas?
JENNIFER E. AMENGUAL

95 Harnessing lymphoma epigenetics to improve therapies*
HAOPENG YANG AND MICHAEL R. GREEN

101 Novel targets in aggressive lymphoma
KAMI MADOCKS

Beyond the Marrow: Major Nonhematologic Complications of Inherited Bone Marrow Failure Syndromes

107 Special pre- and posttransplant considerations in inherited bone marrow failure and hematopoietic malignancy predisposition syndromes
CARMEM BONFIM

115 Extrahematopoietic manifestations of the short telomere syndromes
KRISTEN E. SCHRATZ

Caring for Patients with Acute Leukemia in Community Hospitals: Who, What, and When to Refer?

123 Optimizing management of acute leukemia in community centers and when to refer
ANAND P. JILLELLA, JORGE E. CORTES, AND VAMSI K. KOTA

129 Practice patterns and outcomes for adults with acute myeloid leukemia receiving care in community vs academic settings
ANNA B. HALPERN AND ROLAND B. WALTER

135 Updates in infection risk and management in acute leukemia
C. LOGAN, D. KOURA, AND R. TAPLITZ

Challenging Situations for Patients with Aggressive Lymphomas

140 Approaches to aggressive B-cell lymphomas in less fit patients
NANCY L. BARTLETT

148 Strategies for introducing palliative care in the management of relapsed or refractory aggressive lymphomas
OREOFE O. ODEJIDE

154 Strategies for aggressive T-cell lymphoma: divide and conquer
LAUREN C. PINTER-BROWN

Chronic Transfusion Support: Challenging Cases

160 Challenges in chronic transfusion for patients with thalassemia
ASHUTOSH LAL

167 Outpatient transfusions for myelodysplastic syndromes
ERICA M. WOOD AND ZOE K. McQUILTEN

175 Social aspects of chronic transfusions: addressing social determinants of health, health literacy, and quality of life
JENNIFER WEBB

Diagnostic and Prognostic Models in VTE Management: Ready for Prime Time?

184 Can pregnancy-adapted algorithms avoid diagnostic imaging for pulmonary embolism?
WEE-SHIAN CHAN

190 When I treat a patient with acute pulmonary embolism at home
FREDERIKUS A. KLOK AND MENNO V. HUISMAN

195 EVIDENCE-BASED MINIREVIEW
Advanced therapies and extracorporeal membrane oxygenation for the management of high-risk pulmonary embolism
RADHIKA GANGARAJU AND FREDERIKUS A. KLOK
Which patients are at high risk of recurrent venous thromboembolism (deep vein thrombosis and pulmonary embolism)?
FIONNUALA N´I ´AINLE AND BARRY KEVANE

Genetic Testing for Heritable Hematologic Disorders 101

Informed consent for genetic testing in hematology
JONATHAN M. MARRON

Identifying potential germline variants from sequencing hematopoietic malignancies
IRA L. KRAFT AND LUCY A. GODLEY

Handling Challenging Questions in the Management of CML

First-generation vs second-generation tyrosine kinase inhibitors: which is best at diagnosis of chronic phase chronic myeloid leukemia?
VIVIAN G. OEHLER

How to manage CML patients with comorbidities
JORGE CORTES

Handling challenging questions in the management of chronic myeloid leukemia: when is it safe to stop tyrosine kinase inhibitors?
DELPHINE REA

Immunotherapy in Multiple Myeloma

Sequencing multiple myeloma therapies with and after antibody therapies
NIELS W. C. J. VAN DE DONK

EVIDENCE-BASED MINIREVIEW
Should all newly diagnosed MM patients receive CD38 antibody–based treatment?
CHARLOTTE L. B. M. KORST AND NIELS W. C. J. VAN DE DONK

Bispecifics, trispecifics, and other novel immune treatments in myeloma
GUIDO LANCMAN, JOSHUA RICHTER, AND AJAI CHARI

Future of CAR T cells in multiple myeloma
KITSADA WUDHIKARN, SHAM MAILANKODY, AND ERIC L. SMITH

Improving Symptom Control for Children with Hematological Malignancies

Improving symptom control and reducing toxicities for pediatric patients with hematological malignancies
LILLIAN SUNG, TAMARA P. MILLER, AND ROBERT PHILLIPS

Indolent Lymphomas: Answers to Smoldering Questions

How do I sequence therapy for follicular lymphoma?
GILLES SALLES

How do we sequence therapy for marginal zone lymphomas?
ALESSANDRO BROCCOLI AND PIER LUIGI ZINZANI

Transformed lymphoma: what should I do now?
SONALI SMITH

Infection Risk, Immunization Recommendations, and Antimicrobial Prophylaxis When Treating Nonmalignant Hematologic Disorders

Rituximab and eculizumab when treating nonmalignant hematologic disorders: infection risk, immunization recommendations, and antimicrobial prophylaxis needs
ELISSA R. ENGEL AND JOLAN E. WALTER
<table>
<thead>
<tr>
<th>Page</th>
<th>Title</th>
<th>Authors</th>
</tr>
</thead>
<tbody>
<tr>
<td>319</td>
<td>Practical approach to monitoring and prevention of infectious complications associated with systemic corticosteroids, antimetabolites, cyclosporine, and cyclophosphamide in nonmalignant hematologic diseases</td>
<td>LUIS MALPICA AND STEPHAN MOLL</td>
</tr>
<tr>
<td>328</td>
<td>Preventing infections in children and adults with asplenia</td>
<td>GRACE M. LEE</td>
</tr>
<tr>
<td>336</td>
<td>Managing Toxicities of Targeted Therapies in CLL</td>
<td></td>
</tr>
<tr>
<td>336</td>
<td>Managing toxicities of Bruton tyrosine kinase inhibitors</td>
<td>ANDREW LIPSKY AND NICOLE LAMANNA</td>
</tr>
<tr>
<td>346</td>
<td>Managing toxicities of phosphatidylinositol-3-kinase (PI3K) inhibitors</td>
<td>ASHLEY HANLON AND DANIELLE M. BRANDER</td>
</tr>
<tr>
<td>357</td>
<td>Preventing and monitoring for tumor lysis syndrome and other toxicities of venetoclax during treatment of chronic lymphocytic leukemia</td>
<td>KIRSTEN FISCHER, OTHMAN AL-SAWAF, AND MICHAEL HALLEK</td>
</tr>
<tr>
<td>363</td>
<td>Monoclonal Gammopathies of Determined Significance</td>
<td></td>
</tr>
<tr>
<td>363</td>
<td>Management of AL amyloidosis in 2020</td>
<td>GIOVANNI PALLADINI, PAOLO MILANI, AND GIAMPAOLO MERLINI</td>
</tr>
<tr>
<td>372</td>
<td>Management of Waldenström macroglobulinemia in 2020</td>
<td>JORGE J. CASTILLO AND STEVEN P. TREON</td>
</tr>
<tr>
<td>380</td>
<td>Monoclonal gammopathies of clinical significance</td>
<td>ANGELA DISPENZIERI</td>
</tr>
<tr>
<td>389</td>
<td>More Anxiety-Provoking Hematology Consults</td>
<td></td>
</tr>
<tr>
<td>389</td>
<td>A patient with Gaucher disease and plasma cell dyscrasia: bidirectional impact</td>
<td>ARI ZIMRAN, ROSA RUCHLEMER, AND SHOSHANA REVEL-VILK</td>
</tr>
<tr>
<td>395</td>
<td>Histiocytic disorders: insights into novel biology and implications for therapy of Langerhans cell histiocytosis and Erdheim-Chester disease</td>
<td>KENNETH MCCLAIN</td>
</tr>
<tr>
<td>400</td>
<td>Updates on the diagnosis and management of the most common hereditary porphyrias: AIP and EPP</td>
<td>MICHAEL LINENBERGER AND KLEBER Y. FERTRIN</td>
</tr>
<tr>
<td>411</td>
<td>Myelodysplastic Syndromes: What We Have and What We Want</td>
<td></td>
</tr>
<tr>
<td>411</td>
<td>Existing agents, novel agents, or transplantation for high-risk MDS</td>
<td>BART L. SCOTT</td>
</tr>
<tr>
<td>418</td>
<td>Patient stratification in myelodysplastic syndromes: how a puzzle may become a map</td>
<td>ANNE SOPHE KUBASCH AND UWE PLATZBECKER</td>
</tr>
<tr>
<td>426</td>
<td>Therapy for lower-risk MDS</td>
<td>HETTY E. CARRAWAY AND CANER SAYGIN</td>
</tr>
<tr>
<td>434</td>
<td>Myeloproliferative Disorders: Too Many Cells, Too Few Therapies</td>
<td></td>
</tr>
<tr>
<td>434</td>
<td>Applied genomics in MPN presentation</td>
<td>ALISON R. MOLITerno AND HANNAH KAIZER</td>
</tr>
<tr>
<td>440</td>
<td>Genomics of MPN progression</td>
<td>ANAND A. PATEL AND OLA TOYOSI ODENIKE</td>
</tr>
</tbody>
</table>
Women and bleeding disorders: diagnostic challenges
PAULA D. JAMES

The Brain and Pain in Sickle Cell Disease
Neuropathic pain in sickle cell disease: measurement and management
ALEXANDER GLAROS AND AMANDA M. BRANDOW
Optimizing the management of chronic pain in sickle cell disease
IFEYINWA OSUNKWO, HAZEL F. O’CONNOR, AND ELNA SAAN

The Emerging Role of Targeted Therapies and Cell Therapy in Transplant
Next-generation cell therapies: the emerging role of CAR-NK cells
RAFET BASAR, MAY DAHER, AND KATAYOUN REZVANI
Practical aspects of building a new immunotherapy program: the future of cell therapy
JESÚS G. BERDEJA

Understanding How to Manipulate the Immune System in Immunotherapy for Lymphoma
Fundamentals of immunology for understanding immunotherapy for lymphoma
STEPHEN M. ANSELL
Immunotherapy with cells
ELISE A. CHONG AND DAVID L. PORTER
Immunotherapy with drugs
YUN CHOI AND CATHERINE S. DIEFENBACH

Updates on the Role of Nonanticoagulant Interventions in Venous Thromboembolism
Role of venous stenting for venous thromboembolism
KAREN BREEN
Thrombolytic therapy in acute venous thromboembolism
THITA CHIASAKUL AND KENNETH A. BAUER
Inferior vena cava filters: a framework for evidence-based use
AMAR H. KELKAR AND ANITA RAJASEKHAR
EVIDENCE-BASED MINIREVIEW
Do prophylactic inferior vena cava filters in trauma patients reduce the risk of mortality or pulmonary embolism?
AMAR H. KELKAR AND ANITA RAJASEKHAR

What Hematologists Need to Know About Giving and Stopping Aspirin
Does aspirin prevent venous thromboembolism?
ROBERT DIEP AND DAVID GARCIA
Combining antiplatelet and anticoagulant therapy in cardiovascular disease
GEOFFREY D. BARNES

Yin and Yang of Autoimmunity and Immunodeficiencies in Hematology
Allogeneic hematopoietic stem cell transplantation in adults with primary immunodeficiency
EMMA C. MORRIS
How to evaluate for immunodeficiency in patients with autoimmune cytopenias: laboratory evaluation for the diagnosis of inborn errors of immunity associated with immune dysregulation
ROSHINI S. ABRAHAM
Treatment of immune-mediated cytopenias in patients with primary immunodeficiencies and immune regulatory disorders (PIRDs)
MARKUS G. SEIDEL
Erratum

680 Sanz GF. In MDS, is higher risk higher reward? Hematology Am Soc Hematol Educ Program. 2019;2019:381-390.

*Articles Not Eligible for Continuing Medical Education Credit

95 Harnessing lymphoma epigenetics to improve therapies
HAOPENG YANG AND MICHAEL R. GREEN

590 Immunotherapy with cells
ELISE A. CHONG AND DAVID L. PORTER